Iradimed Co (IRMD) - Net Assets
Based on the latest financial reports, Iradimed Co (IRMD) has net assets worth $94.62 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($108.78 Million) and total liabilities ($14.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Iradimed Co (IRMD) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $94.62 Million |
| % of Total Assets | 86.98% |
| Annual Growth Rate | 29.7% |
| 5-Year Change | 31.1% |
| 10-Year Change | 196.71% |
| Growth Volatility | 73.51 |
Iradimed Co - Net Assets Trend (2012–2025)
This chart illustrates how Iradimed Co's net assets have evolved over time, based on quarterly financial data. Also explore Iradimed Co total assets for the complete picture of this company's asset base.
Annual Net Assets for Iradimed Co (2012–2025)
The table below shows the annual net assets of Iradimed Co from 2012 to 2025. For live valuation and market cap data, see IRMD market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $94.62 Million | +8.98% |
| 2024-12-31 | $86.82 Million | +21.56% |
| 2023-12-31 | $71.42 Million | -3.06% |
| 2022-12-31 | $73.67 Million | +2.08% |
| 2021-12-31 | $72.17 Million | +17.58% |
| 2020-12-31 | $61.38 Million | +10.55% |
| 2019-12-31 | $55.52 Million | +32.37% |
| 2018-12-31 | $41.95 Million | +27.38% |
| 2017-12-31 | $32.93 Million | +3.27% |
| 2016-12-31 | $31.89 Million | -0.14% |
| 2015-12-31 | $31.93 Million | +52.86% |
| 2014-12-31 | $20.89 Million | +285.24% |
| 2013-12-31 | $5.42 Million | +68.40% |
| 2012-12-31 | $3.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Iradimed Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5544.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $64.23 Million | 67.88% |
| Common Stock | $1.00K | 0.00% |
| Other Components | $30.39 Million | 32.11% |
| Total Equity | $94.62 Million | 100.00% |
Iradimed Co Competitors by Market Cap
The table below lists competitors of Iradimed Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BrightView Holdings
NYSE:BV
|
$1.11 Billion |
|
Luoniushan Co Ltd
SHE:000735
|
$1.11 Billion |
|
TUYA INC.ADR/1A
F:785
|
$1.11 Billion |
|
Sichuan Xunyou Network Technology Co Ltd
SHE:300467
|
$1.11 Billion |
|
Jiangsu Riying Electns Co Ltd
SHG:603286
|
$1.11 Billion |
|
Rimon Consulting & Management Services Ltd
TA:RMON
|
$1.11 Billion |
|
Zhejiang Great Southeast Co Ltd
SHE:002263
|
$1.11 Billion |
|
Chimera Investment Corporation
NYSE:CIM
|
$1.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Iradimed Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 86,818,756 to 94,618,000, a change of 7,799,244 (9.0%).
- Net income of 22,480,000 contributed positively to equity growth.
- Dividend payments of 15,040,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $22.48 Million | +23.76% |
| Dividends Paid | $15.04 Million | -15.9% |
| Other Changes | $359.24K | +0.38% |
| Total Change | $- | 8.98% |
Book Value vs Market Value Analysis
This analysis compares Iradimed Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 281.89x to 11.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.31 | $87.15 | x |
| 2013-12-31 | $0.52 | $87.15 | x |
| 2014-12-31 | $2.04 | $87.15 | x |
| 2015-12-31 | $2.54 | $87.15 | x |
| 2016-12-31 | $2.66 | $87.15 | x |
| 2017-12-31 | $2.81 | $87.15 | x |
| 2018-12-31 | $3.46 | $87.15 | x |
| 2019-12-31 | $4.52 | $87.15 | x |
| 2020-12-31 | $4.93 | $87.15 | x |
| 2021-12-31 | $5.73 | $87.15 | x |
| 2022-12-31 | $5.83 | $87.15 | x |
| 2023-12-31 | $5.61 | $87.15 | x |
| 2024-12-31 | $6.79 | $87.15 | x |
| 2025-12-31 | $7.36 | $87.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Iradimed Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.76%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.82%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.15x
- Recent ROE (23.76%) is above the historical average (18.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 30.00% | 12.57% | 1.38x | 1.72x | $644.07K |
| 2013 | 35.72% | 17.08% | 1.62x | 1.29x | $1.39 Million |
| 2014 | 9.81% | 13.10% | 0.67x | 1.12x | $-38.70K |
| 2015 | 23.58% | 23.83% | 0.90x | 1.10x | $4.34 Million |
| 2016 | 22.62% | 22.20% | 0.87x | 1.17x | $4.03 Million |
| 2017 | 1.52% | 2.17% | 0.59x | 1.18x | $-2.79 Million |
| 2018 | 15.03% | 20.71% | 0.63x | 1.15x | $2.11 Million |
| 2019 | 17.35% | 25.00% | 0.58x | 1.20x | $4.08 Million |
| 2020 | 2.23% | 4.32% | 0.45x | 1.16x | $-4.77 Million |
| 2021 | 12.92% | 22.30% | 0.50x | 1.15x | $2.11 Million |
| 2022 | 17.41% | 24.06% | 0.62x | 1.16x | $5.46 Million |
| 2023 | 24.07% | 26.22% | 0.71x | 1.29x | $10.05 Million |
| 2024 | 22.15% | 26.26% | 0.74x | 1.13x | $10.55 Million |
| 2025 | 23.76% | 26.82% | 0.77x | 1.15x | $13.02 Million |
Industry Comparison
This section compares Iradimed Co's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Iradimed Co (IRMD) | $94.62 Million | 30.00% | 0.15x | $1.11 Billion |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Iradimed Co
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring syst… Read more